Enhancement of Anti-telemorase Immunity Against Prostate Cancer
Abstract
The objectives of this award include a series of scientific studies to a) reverse tumor-mediated immunosuppression in metastatic prostate cancer patients and b) stimulate therapeutic antitumor immunity in the tumor bearing host using active immunotherapy interventions. Over the course of the grant, Dr. Vieweg and his team have explored several strategies to phenotypically and functionally define both regulatory T cells (Treg) as well as myeloid-derived suppressor cells (MDSC) in the peripheral blood of advanced cancer patients. We also have developed and explored targeted pharmacological interventions to abrogate either Treg or MDSC-induced immunosuppression. As shown below, considerable progress has been made in the laboratory to define these regulatory pathways and to explore these new concepts in ongoing or planned clinical studies, as described below and as demonstrated by the published data shown in references 1-4.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2010
- Accession Number
- AD1035452
Entities
People
- Johannes Vieweg
Organizations
- University of Florida